Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox

Category

North America

Coverage of the United States and Canada: coverage determinations, drug pricing policy, regulatory decisions and the assessment bodies that inform them.

358 articles in this topic.

Articles in this category

Ivonescimab Complete Response Letter: FDA Lists Four Reasons

11/18/2026

Ivonescimab Complete Response Letter: FDA Lists Four Reasons

The FDA complete response letter for ivonescimab (BLA 761524) cites China-heavy trial data, a modest PFS gain and the need for a new multiregional trial. Summit must resubmit or take another action within one year.
Read Article →
FDA Launches Global Reliance Disclosure Program for Approval Packages

11/18/2026

FDA Launches Global Reliance Disclosure Program for Approval Packages

The FDA's Global Reliance Disclosure Program lets companies pass minimally redacted approval packages to regulators outside the US. Lenacapavir is the launch case, and the FDA intends to widen the program in January 2027. #SyenzaNews #MarketAccess
Read Article →
FDA Rejects Ivonescimab Lung Cancer Treatment Over Survival Gap

11/17/2026

FDA Rejects Ivonescimab Lung Cancer Treatment Over Survival Gap

FDA rejects ivonescimab lung cancer treatment: the trial slowed progression, but the overall survival benefit did not reach statistical significance.
Read Article →
Learning Health System Frameworks and AI in US Care: A Scoping Review

11/16/2026

Learning Health System Frameworks and AI in US Care: A Scoping Review

A scoping review of 54 learning health system framework studies and 31 AI studies in US care finds that AI work mostly stops at turning data into knowledge. Only three AI studies reached practice, and none described feedback from deployment back into the model. #SyenzaNews #MarketAccess
Read Article →
ACS Updates Prostate Cancer Screening Guideline for PSA Testing

11/13/2026

ACS Updates Prostate Cancer Screening Guideline for PSA Testing

"The American Cancer Society has updated its prostate cancer screening guideline, with regular PSA testing for average-risk men aged 50 to 69." #SyenzaNews #ProstateCancer
Read Article →
Aspen Gets Approval for Generic Semaglutide in Brazil and South Africa

11/12/2026

Aspen Gets Approval for Generic Semaglutide in Brazil and South Africa

Aspen Pharmacare has received approval for generic semaglutide in Brazil and South Africa, following Canada in July. Launches in all three markets are expected over the coming months. #SyenzaNews #MarketAccess
Read Article →
US MFN Drug Pricing: A 25% German Price Rise Would Cut Medicaid Savings by 3.8%

11/12/2026

US MFN Drug Pricing: A 25% German Price Rise Would Cut Medicaid Savings by 3.8%

A preprint led by Thomas Hwang models how German price changes affect US Medicaid MFN savings and German statutory health insurance spending.
Read Article →
FDA Adds Warning on NAION Risk with GLP-1 Receptor Agonists

11/10/2026

FDA Adds Warning on NAION Risk with GLP-1 Receptor Agonists

FDA is requiring every GLP-1 receptor agonist label to carry a warning on NAION, a rare eye condition that can cause permanent vision loss. #SyenzaNews #drugsafety #GLP1
Read Article →
Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo

11/10/2026

Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo

The FDA approved Sunharbo (asundexian), the first factor XIa inhibitor for stroke prevention, for adults after a recent ischemic stroke or high-risk TIA. #SyenzaNews #MarketAccess
Read Article →
CMS Finalizes GLOBE Model Drug Pricing for Medicare Part B Drugs

11/9/2026

CMS Finalizes GLOBE Model Drug Pricing for Medicare Part B Drugs

CMS finalizes the GLOBE Model drug pricing rule, benchmarking Medicare Part B drug rebates against international prices from April 2027. #SyenzaNews #MarketAccess
Read Article →
Medicare drug price negotiation: CMS sets permanent rules

11/9/2026

Medicare drug price negotiation: CMS sets permanent rules

The final rule also covers a temporary price floor for small biotech drugs and Part D plan payments to dispensing entities. #SyenzaNews #DrugPricing #MarketAccess
Read Article →
Zepbound and Foundayo telehealth access via Hims & Hers

11/9/2026

Zepbound and Foundayo telehealth access via Hims & Hers

Eli Lilly and Hims & Hers Health agreed to widen Zepbound and Foundayo telehealth access, with self-pay prices starting at $149 per month. #SyenzaNews #obesity #telehealth
Read Article →

Related topics